Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda ...

The drugmaker posted $16.29 billion in quarterly revenue, topping Wall Street forecasts, though a big acquisition charge ...

What is Keytruda and how does it work? Experts explain the cancer immunotherapy as a global investigation raises concerns ...

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells. Experts say it offers improved outcomes in several advanced cancers and ...

Merck's Q1 sales surpassed expectations, driven by strong demand for Keytruda. Despite acquisition-related losses, investors ...

By Deena Beasley and Mariam Sunny April 30 (Reuters) - Merck on Thursday beat first-quarter sales expectations on strong ...

In a yearlong investigation led by the International Consortium of Investigative Journalists, reporters from more than 37 ...